Compare BLIN & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLIN | GTBP |
|---|---|---|
| Founded | 2000 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 13.0M |
| IPO Year | 2018 | 2016 |
| Metric | BLIN | GTBP |
|---|---|---|
| Price | $0.87 | $7.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.62 | N/A |
| AVG Volume (30 Days) | 28.8K | ★ 350.3K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,568,000.00 | N/A |
| Revenue This Year | $22.67 | N/A |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.22 |
| 52 Week High | $1.59 | $8.82 |
| Indicator | BLIN | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 26.04 | 70.84 |
| Support Level | $0.82 | $0.36 |
| Resistance Level | $0.87 | N/A |
| Average True Range (ATR) | 0.05 | 0.91 |
| MACD | -0.00 | 0.89 |
| Stochastic Oscillator | 5.77 | 66.49 |
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.